Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study - Quiz - MDSpire

Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study

  • By

  • Xue Ding

  • Zhengye Wang

  • Hong Zhang

  • Li Dai

  • Huaxing Ma

  • Guangxian Leng

  • Yunshan Yang

  • Yongjin Zhou

  • Siqi Luo

  • Qian Wang

  • Xiangren Jin

  • July 15, 2026

Share

Original Source(s)

Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study

  • by Xue Ding, Zhengye Wang, Hong Zhang, Li Dai, Huaxing Ma, Guangxian Leng, Yunshan Yang, Yongjin Zhou, Siqi Luo, Qian Wang, Xiangren Jin

  • July 15, 2026

Related Content

Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman

Prediction models for postoperative recurrence in papillary thyroid carcinoma: a systematic review and critical appraisal

Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis